Drug Trial Radar · NCT01803477
Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
37
Actual
Start
Feb 2013
Primary completion
Oct 2013
Study completion Dec 2013
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 4, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if the new vehicle formulations containing ingenol mebutate are as safe and effective as Picato® gel 0.05% (it's current vehicle formulation) when applied to AK lesions on the forearm for two consecutive days.
Conditions
- Actinic Keratosis
Interventions
once daily for two consecutive days (Picato)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of 3 new vehicle formulations containing ingenol mebutate compared to Picato® gel applied topically once daily for two consecutive days to four separate treatment areas containing actinic keratosis on the forearmTime frame: 2 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dermatology Department
Woolloongabba, Queensland, Australia
Specialist Connect
Woolloongabba, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.